FDA orders overdose warnings for Darvocet

Jul 07, 2009 By LAURAN NEERGAARD , AP Medical Writer

(AP) -- The government is letting the painkillers Darvocet, Darvon and their generic cousins stay on the market but ordered stronger warnings against deadly overdoses on Tuesday.

The Food and Drug Administration's decision puts the U.S. in stark contrast to Britain - which banned the drugs several years ago, citing a trail of suicides and accidental overdoses - and Europe's drug regulators, which just recommended that European Union countries do the same.

Known generically as propoxyphene, the 50-year-old prescription drug is widely used in the U.S. even though doctors consider it a weak pain reliever. The consumer watchdog group Public Citizen had petitioned the FDA to ban it here, too, saying the small benefit didn't justify a risk that was adding up to several hundred deaths a year. In January, the FDA's scientific advisers narrowly agreed.

But the FDA overruled its advisers Tuesday, at least for now. It ordered that a stern boxed warning be placed on the drug's label, and that patients soon start receiving a special pamphlet with every bottle that stresses the risk of taking too much.

Also Tuesday, FDA ordered manufacturer Xanodyne Pharmaceuticals Inc. of Newport, Ky., to study the effect of higher-than-recommended doses on patients' hearts, saying the findings could lead to additional actions. And the agency is seeking help from Medicare and the Department of Veterans Affairs to further study the drug's specific effects in the elderly.

For now, FDA decided "this is an acceptable option for patients," said agency drug chief Dr. Janet Woodcock, stressing that other painkillers come with their own sets of side effects.

Indeed, just last week another panel of FDA's advisers warned against from overdoses of over-the-counter acetaminophen, the in and numerous other drug brands - and the agency is considering restrictions on that drug, too.

As for Darvon and Darvocet, Public Citizen is considering whether to appeal FDA's decision or to sue over it.

"This is a reckless decision on the part of the FDA unless they believe Americans are resistant to the death-causing properties of this drug in a way that Europeans and people in the U.K. aren't," said Public Citizen's Dr. Sidney Wolfe. "You've got a drug which has a barely perceptible benefit and a very clear risk."

A large enough dose of many pain relievers can kill, making it hard to use medication regulation to guard against suicide.

But Wolfe worries about longtime Darvon and Darvocet users who inch up their dose in hopes of better pain relief. A heart-toxic metabolite of the drug can linger in the body for 30 hours, so as little as one or two extra pills each time a dosage is due could quickly add up to damaging levels, Wolfe said. Too much can eventually interrupt the heart's electrical activity, a deadly condition known as heart block, he said.

By the FDA's count, about 21 million prescriptions were written for propoxyphene-containing drugs in 2007. Most popular is Darvocet or its generic equivalent, which combines the narcotic propoxyphene with the more common painkiller acetaminophen. At FDA's January meeting on the drug, officials cited studies showing most of the pain relief from Darvocet came from the acetaminophen component.

Wolfe cited data from the government's Drug Abuse Warning Network, which tracks emergency room visits, that counted 503 Darvon-related deaths in 2007, about 20 percent of them classified as suicides.

Britain phased the drug off the market, between 2005 and the end of 2007, to give patients time to switch to other painkillers. A recent study in the British Medical Journal tracked a drop in propoxyphene-related deaths as prescriptions plummeted during that period, and researchers calculated that 349 deaths were prevented.

©2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Explore further: Experts want restrictions on testosterone drug use (Update)

add to favorites email to friend print save as pdf

Related Stories

FDA weighs options to reduce painkiller overdoses

Jun 29, 2009

(AP) -- Tylenol, Excedrin, NyQuil. These household brands and others have come to symbolize safe, convenient relief from the aches and pains of everyday life. But this week the Food and Drug Administration ...

FDA cracks down on unapproved narcotic painkillers

Mar 31, 2009

(AP) -- The government ordered 14 unapproved narcotic painkillers off the market Tuesday, prescription versions of potent morphine, hydromorphone and oxycodone. The Food and Drug Administration told nine manufacturers to ...

FDA panel: Lower maximum daily dose of Tylenol

Jun 30, 2009

(AP) -- Government experts called for sweeping safety restrictions Tuesday on the most widely used painkiller, including reducing the maximum dose of Tylenol and eliminating prescription drugs such as Vicodin ...

FDA panel to vote on painkiller restrictions

Jun 30, 2009

(AP) -- Government experts are scheduled to vote on whether Nyquil and other combination cold medications should be pulled from the market to help curb deadly overdoses.

FDA group recommends acetaminophen liver warnings

May 27, 2009

(AP) -- A Food and Drug Administration report released Wednesday recommends stronger warnings and dose limits on drugs containing the painkiller acetaminophen, citing an increased risk of liver injury.

Recommended for you

Experts want restrictions on testosterone drug use (Update)

20 hours ago

Federal health experts said Wednesday there is little evidence that testosterone-boosting drugs are effective for treating common signs of aging in men and that their use should be narrowed to exclude millions of Americans ...

Big cities take aim at prescription painkillers

Sep 16, 2014

Some of the nation's largest cities are ratcheting up their criticism of prescription painkillers, blaming the industry for a wave of addiction and overdoses that have ravaged their communities and busted local budgets.

World Health Organization policy improves use of medicines

Sep 16, 2014

In this issue of PLOS Medicine, Kathleen Holloway from WHO and David Henry (University of Toronto, Canada) evaluated data on reported adherence to WHO essential medicines practices and measures of quality use of medicines from 5 ...

User comments : 0